Research programme: cardiovascular diagnostic imaging - Pharmacyclics
Latest Information Update: 28 Nov 2007
At a glance
- Originator Pharmacyclics
- Developer Johns Hopkins University School of Medicine; Pharmacyclics
- Class Gadolinium-containing contrast agents; Texaphyrins
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery disease
Most Recent Events
- 04 Jun 2004 Pharmacyclics is looking for a collaborative partner for the programme
- 03 Jun 2004 Preclinical trials in Coronary artery disease (diagnosis) in USA (unspecified route)